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Abstract Treatment with TNFα inhibitors increases risk of
reactivating a latent tuberculosis\infection (LTBI). There-
fore screening, prior to therapy with TNFα inhibitors, has
been recommended, even in low-endemic areas such as
well-developed Western Europe countries. We evaluated
interferon-gamma release assay (IGRA), as opposed to
tuberculin skin test (TST), for detection of LTBI in
refractory inflammatory disease patients prior to the
initiation of a first TNFα inhibitor. In addition, we
evaluated the impact of impaired cellular immunity on
IGRA. Patients starting on TNFα inhibition were screened
for LTBI by TST and IGRA (Quantiferon-TB Gold). Data
on tuberculosis exposure and Bacillus Calmette–Guérin
(BCG) vaccination were obtained. Cellular immunity was
assessed by CD4
+ T lymphocyte cell count. Nine out of 56
patients (16.1%) tested positive for LTBI. A concordant
positive result was present in three patients with a medical
history of tuberculosis exposure. Six patients with discor-
dant test results had either: (1) a negative TST and positive
IGRA in combination with a medical history of tuberculosis
exposure (n=1) or (2) a positive TST and negative IGRA in
combination with BCG vaccination (n=3) or a medical
history of tuberculosis exposure (n=2). CD4
+ T lympho-
cyte cell counts were within normal limits, and no
indeterminate results of IGRA were present. IGRA appears
reliable for confirming TST and excluding a false positive
TST (due to prior BCG vaccination) in this Dutch serie of
patients. In addition, IGRA may detect one additional case
of LTBI out of 56 patients that would otherwise be missed
using solely TST. Immune suppression appears not to result
significantly in lower CD4
+ T lymphocyte cell counts and
indeterminate results of IGRA, despite systemic corticoste-
roid treatment in half of the patients. Confirmation in larger
studies, including assessment of cost-effectiveness, is
required.
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Introduction
Tumor necrosis factor α (TNFα) is a regulating cytokine
with a central role in the pathogenesis of chronic
inflammatory disease and thereby a well-defined target for
intervention. In concordance with this, inhibitors of TNFα
have become increasingly important in treatment of a broad
spectrum of rheumatic diseases such as rheumatoid arthritis
[1], psoriatic arthritis [2], ankylosing spondylitis [3],
juvenile inflammatory arthritis [4], adult onset Still’s
disease [5], and sarcoidosis [6]. However, TNFα is also
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viruses, bacteria, and fungi, and therapeutic inhibition of
TNFα may elicit risk of opportunistic infections [7, 8], in
particular, tuberculosis [9, 10]. Thus, screening for LTBI
before TNFα inhibition has been recommended, however,
no gold standard for detecting LTBI exists today and
guidelines have provided conflicting recommendations
about the place of diagnostic screening tests such as
tuberculin skin test (TST) and interferon-gamma release
assay (IGRA).
TST has several limitations as a diagnostic test in detecting
LTBI. Firstly, TST attempts to measure cell-mediated immu-
nity by delayed-type hypersensitivity response to purified
protein derivate (PPD)—i.e., a crude mixture of mycobacteria
antigens. This results in false positive results in non-
tuberculosis mycobacterium infection and clinically more
important, in Bacillus Calmette–Guérin (BCG)-vaccinated
persons [11, 12]. Secondly, TST sensitivity is lower in
immunocompromised patients, possibly due to impaired T
cell function and impaired cellular immunity [13]. And
thirdly, TST has practical disadvantages such as inconve-
nience (two patient visits) and interobserver variability [14].
With respect to these limitations, an in vitro T cell-based
assay has been developed, detecting interferon-gamma in
response to contact with antigens highly specific for
tuberculosis mycobacteria (ESAT-6, CFP-10, and TB 7.7).
This IGRA is not influenced by contact with non-
tuberculosis mycobacteria or prior vaccination with BCG
[15, 16]. Moreover, it is suggested that IGRA has higher
sensitivity in comparison to TST in patients receiving
immunosuppressive treatment [13, 17, 18]. In summary,
although some evidence exists that IGRA has a better
performance in screening of LTBI before starting TNFα
inhibition, the true value of IGRA as a diagnostic tool, with
respect to TST, is ill-defined.
The objective of this study was to compare TST and
IGRA (Quantiferon-TB Gold) in detecting LTBI in refrac-
tory inflammatory disease patients prior to the initiation of
a first TNFα inhibitor. In addition, we evaluated the impact
of cellular immunity on IGRA.
Materials and methods
Between 2008 and 2009, we prospectively enrolled patients
with chronic immune-mediated inflammatory diseases
starting on TNFα inhibition. Patients were recruited from
the rheumatology outpatient clinic of the Medical Center of
Leeuwarden, The Netherlands. Patients with rheumatoid
arthritis, ankylosing spondylitis, psoriatic arthritis, and
juvenile idiopathic arthritis (fulfilling American College of
Rheumatology criteria), and two patients with sarcoidosis
and Still’s disease refractory to treatment with cortico-
steroids and methotrexate, were included. The decision to
start TNFα inhibition was made in agreement with criteria
of the Dutch Society of Rheumatology [19]. The following
variables were collected: gender, age, diagnosis, disease
duration, and immunosuppressive treatment (type and
dosage) at study inclusion. Tuberculosis exposure was
assessed by personal and family medical history, previous
treatment with tuberculostatic, and BCG vaccination. Chest
radiographs were negative for (active) tuberculosis infec-
tion in all patients. Patients were tested for LTBI by TST
and IGRA (Quantiferon-TB Gold). TNFα inhibition was
initiated after a concordant negative TST and IGRA.
Patients with discordant or concordant positive test results
received adequate tuberculostatic treatment before initiation
of TNFα inhibition except for BCG-vaccinated patients
with positive TST, negative IGRA, and negative medical
history.
TST was performed by intradermal injection of 0.1 ml of
PPD at the flexor surface of the upper one third of the
forearm according to the Mantoux method. The diameter of
skin induration was assessed 48–72 h after inoculation by a
trained rheumatologic nurse. A positive TST was defined as
≥5 mm induration according to the Dutch guidelines [19].
Immediately after the intradermal injection of PPD, a
heparinized whole blood sample was collected and trans-
ferred to three Quantiferon
R-TB gold test tubes (Cellestis
Ltd, Australia) to prohibit a booster effect. IGRA was
performed and interpreted according to instructions of the
manufacturer and guideline of Centers of Disease Control
and Prevention [20], respectively. An EDTA tube was
collected for assessment of cellular immunity by CD4
+ cell
T lymphocyte count (CD4
+ cell count).
Results
Patient characteristics Twenty-nine out of 56 included
patients were diagnosed with rheumatoid arthritis (51.8%)
of whom 83.3% were rheumatoid factor positive (Table 1).
Other diagnoses were ankylosing spondylitis (30.4%),
psoriatic arthritis (8.9%), undifferentiated spondylarthrop-
athy (3.6%), juvenile idiopathic arthritis (1.8%), adult onset
Still’s disease (1.8%), and sarcoidosis (1.8%). Mean (± SD)
age of the total study population was 50.3±15.4 years, and
disease duration was 8.7±9.2 years. About half of the study
population (48.2%) had received methotrexate (± cortico-
steroids), 5.4% leflunomide (± methotrexate ± cortico-
steroids), 1.8% azathioprine and corticosteroids, 5% only
corticosteroids, and 35.7% did not had previous immuno-
suppressive treatment. Dosage of immunosuppressive treat-
ment is listed in Table 1. The incidence of BCG vaccination
in the total investigated population was 5% which is
representative of a post-World War II population. Tubercu-
506 Clin Rheumatol (2011) 30:505–510losis exposure was 14% and is in line with the low
prevalence of tuberculosis in Western Europe countries.
The absence of reactivation of tuberculosis during TNFα
inhibition in the BCG-vaccinated patients ruled out the
coexistence of BCG vaccination and prior tuberculosis
exposure in this population.
Comparison of TST and IGRA Nine out of 56 patients
(16.1%) tested positive for LTBI with either TST or IGRA
(Table 2). A concordant positive result was present in three
patientswithamedicalhistoryoftuberculosisexposure.Insix
patients, discordant results were obtained: one patient had a
negative TST and positive IGRA, and five patients had a
positive TST and negative IGRA. The mother of the patient
with negative TST and positive IGRA had suffered from
tuberculosis during his childhood. The five patients with
positive TSTand negative IGRAwere either BCG-vaccinated
(three patients) or had a medical history of tuberculosis
exposure (two patients). The BCG-vaccinated patients with
positive TSTand negative IGRA did not develop tuberculosis
during TNFα inhibition in the follow-up period (1–2y e a r s ) .
Interestingly, there were no indeterminate results of IGRA.
Cellular immunity CD4
+ cell counts were within normal
limits with a mean (± SD) of 964±568 cells/mm
3 (Fig. 1).
A CD4
+ cell count below 300 cells/mm
3 was present in two
patients receiving methotrexate and low-dose corticoste-
roids. These two patients had a negative result for TST and
IGRA and did not develop tuberculosis during TNFα
inhibition (2 years of follow-up). There were no patients
with a CD4
+ cell count below 200 cells/mm
3.
Discussion
The objective of this study was to compare TST and IGRA
(Quantiferon-TB Gold) in detecting LTBI in refractory
Patient characteristics No. (%)
Male 32 (53.6%)
Age (mean±SD) 50.3±15.4 years
Diagnosis
Rheumatoid arthritis
a 29 (51.8%)
RF positive 25 (83.3%)
Ankylosing spondylitis
a 17 (30.4%)
Psoriatic arthritis
a 5 (8.9%)
Undifferentiated spondylitis 2 (3.6%)
Juvenile idiopathic arthritis
a 1 (1.8%)
Still’s disease 1 (1.8%)
Sarcoidosis 1 (1.8%)
Disease duration (mean±SD)
Total study population 8.7±9.2 years
Rheumatoid arthritis 7.4±7.7 years
Type of immunosuppressive treatment (at study inclusion)
Methotrexate ± corticosteroids 27 (48.2%)
Leflunomide ± methotrexate ± corticosteroids 3 (5.4%)
Azathioprine and corticosteroids 1 (1.8%)
Only corticosteroids (maintenance and high-dose treatment) 5 (8.9%)
No current immunosuppressive treatment 20 (35.7%)
Daily dose of immunosuppressive treatment (at study inclusion; mean±SD)
Methotrexate 19±7 mg
Leflunomide 20±0 mg
Azathioprine 150 mg
Corticosteroids
Maintenance treatment 6±2 mg
High-dose treatment
b 3,000±0 mg
BCG vaccination 3 (5%)
Tuberculosis exposure 8 (14%)
Table 1 Patient characteristics
of 56 patients
Data are presented as number
(No.) and percentage (%) and, if
applicable, mean±standard de-
viation (SD)
No. number of patients, RF
rheumatoid factor
a Diagnosis according to the
American College of Rheumatolo-
gy criteria
bOnce-only three pulses of 1 g
methylprednisolone prior to LTBI
screening (n=3)
Clin Rheumatol (2011) 30:505–510 507inflammatory disease patients prior to the initiation of a first
TNFα inhibitor. A well-recognized problem in screening
for LTBI is absence of a gold standard and thereby
sensitivity and specificity of TST and IGRA cannot be
directly measured. Nevertheless, assessment of tuberculosis
exposure, combined with results of TST and IGRA, may
roughly estimate the a priori chance of LTBI.
Nine out of 56 patients (16.1%) tested positive for LTBI
with either TST or IGRA. A concordant positive result was
present in three patients with a medical history of
tuberculosis exposure. The remaining six patients with
discordance had either a negative TST and positive IGRA
(one patient) or a positive TST and negative IGRA (five
patients). The discordance in the five patients with positive
TST and negative IGRA can be attributed to BCG
vaccination (three patients) or a medical history of
tuberculosis exposure (two patients). As for the patients
with negative IGRA and positive TST, it cannot be
excluded that IGRA may be false negative as the infection
occurred in the distant past. This may be explained by the
fact that IGRA mostly measures effector T cell responses
whereas TST measures both effector and memory T cell
responses. After 24 h incubation in the IGRA, only
circulating effector memory T cells have sufficient time to
produce interferon, while central memory T cells first
started producing interferon after a more prolonged (72 h
in TST) incubation [21]. The Quantiferon-TB Gold per-
forms well in routine screening of low-prevalence popula-
tions, but its performance turned out to be suboptimal in
healthy persons with a high risk of tuberculosis exposure
[22]. It is also known that the sensitivity of the Quantiferon
depends on the test and is higher for the latest in-tube
version that was used in this study [23]. Indeed, we found a
low number (n=1) of discordant negative TST and positive
IGRA in a low tuberculosis-exposed population.
Indeterminate results of IGRA are commonly reported in
patients with, e.g., HIV, malignancy, and chronic renal
failure, and patients undergoing immunosuppressive treat-
ment [24, 25]. In comparison with studies in rheumatic
disease patients [26–32], it is remarkable that in this study
IGRA could be interpreted without problems—i.e., there
were no indeterminate results. This suggests that lympho-
cytes retained the capacity to produce interferon-gamma on
Table 2 Characteristics of nine patients with concordant positive TST and IGRA and discordant TST and IGRA
N TST IGRA BCG Tuberculosis exposure CD4
+ count (cells/mm
3) Medication (daily dose in mg) Diagnosis
Concordant positive results of TST and IGRA
1 pos. pos. no yes 748 MTX 12.5; lef 20 PsA
2 pos. pos. no yes 972 MTX 25 RA
3 pos. pos. no yes N.A. none AS
Discordant results of TST and IGRA
1 neg. pos. no yes 974 MTX 15 RA
2 pos. neg. yes no 590 pred 5; MTX 10; lef 20 RA
3 pos. neg. yes no 387 MTX 25 RA
4 pos. neg. yes no 2,050 MTX 7.5 PsA
5 pos. neg. no yes 632 none AS
6 pos. neg. no yes 549 MTX 7.5 RA
N patient number, TST tuberculosis skin test, IGRA interferon-gamma release assay (Quantiferon-TB Gold), BCG Bacillus Calmette–Guérin, TB
tuberculosis, CD4
+ count CD4
+ T lymphocyte cell count, pos. positive, neg. negative, N.A. not available, MTX methotrexate, pred prednisone, lef
leflunomide, PsA psoriatic arthritis, RA rheumatoid arthritis, AS ankylosing spondylitis
N=56 N=5 N=27 N=3 N=1 N=20
0
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Fig. 1 Cellular immunity defined by immunosuppressive treatment
and CD4
+ T lymphocyte cell count (cells/mm
3) at study inclusion.
Data are given as mean±standard deviation (SD)
508 Clin Rheumatol (2011) 30:505–510mitogen stimulation in vitro, even with immunosuppressive
treatment. Although we do not have a representative control
group, it appears that CD4
+ cell count in this study
population was not greatly reduced in response to immu-
nosuppressive treatment—i.e., CD4
+ cell counts were not
below 200 cells/mm
3 and only two patients had a CD4
+ cell
count below 300 cells/mm
3. Furthermore, the two patients
with a positive TST, a negative IGRA and an positive
medical history of LTBI had both a normal CD4
+ cell
count.
The absence of a significant influence of immunosup-
pressive treatment on interpretation of IGRA in patients
with inflammatory rheumatic conditions has previously
been reported by Matulis [27]. Cellestis stated that as long
as the viable CD4
+ cell count is above 200 cells/mm
3
Quantiferon-TB Gold has a good performance. However, it
has been questioned whether CD4
+ cell count can be used as
a marker of validity of IGRA in patients other than HIV
patients [28]. Furthermore, the intrinsic function of T cells
may be an important precondition for the capacity of
interferon production. Two studies analyzing the impact of
different classes of drugs on the response of TST and IGRA
in European patients with immune-mediated inflammatory
diseases stated that corticosteroid treatment can in fact
compromise test results by increasing the number of
indeterminate results of IGRA and negative TST outcomes
[27, 29]. We therefore hypothesize that high-dose corticoste-
roid maintenance therapy may be a risk factor for an
indeterminate IGRA result. Possibly, the absence of indeter-
minate test IGRA results in our study was due to the low-
dose corticosteroids (10 mg per day at most). Overall,
sensitivity of IGRA for the diagnosis of LTBI might be
higher than TST, despite a higher rate of indeterminate
results in immunocompromised patients [26–32].
Various recommendations and guidelines have been
issued to determine the place of diagnostic screening test
for LTBI. They are traditionally based on medical history,
chest X-ray and TST. Two leading institutes, the Centers of
Disease Control and Prevention (CDC) of the United States
and United Kingdom’s National Institute for health and
Clinical Excellence (NICE), have developed guidelines
regarding correct usage of both diagnostic tools [20, 33],
but they came to conflicting conclusions. The CDC stated
that IGRA is a real alternative for TST whereas NICE
advised the use of IGRA only for the validation of a
positive TST. The variation in prevalence of tuberculosis
over time in different parts of the world may account for
this disagreement. Western Europe has a substantially larger
BCG-vaccinated population as compared to the United
States of America (USA). Therefore, the addition of IGRA
augments the specificity of prescreening in Western Europe.
Furthermore, most cases of LBTI in Western Europe
occurred in a population born before 1945. A lower
performance of IGRA in Europe as compared to the USA
may be attributed to a low sensitivity in the case of longer
duration of LTBI. In different countries of Western Europe
IGRA is currently added in a second step approach
according to NICE or is even replacing TST (Germany,
Switzerland) [34, 35]. We feel that all physicians, including
rheumatologists, who treat different immune-mediated
inflammatory diseases, are obliged to hand tailor the
prophylactic therapy for LTBI by the prevalence of
tuberculosis and BCG vaccination of their country.
In conclusion, the findings of this study suggest that
IGRA appears reliable for confirming a positive TST and
excluding a false positive result (in case of prior BCG
vaccination) in this Dutch serie of patients. IGRA may
thereby reduce the number of patients in whom tuber-
culostatics are prescribed in absence of LTBI, resulting in
an evident benefit of avoiding a 6-month delay of effective
anti-rheumatic treatment with TNFα inhibition and possible
side effects due to treatment with tuberculostatics. More-
over, IGRA seems to detect an additional case of LTBI that
otherwise be missed using solely TST. IGRA appears not to
be significantly influenced by immunosuppressive treat-
ment, at least not by the regimen and dosage used in this
study. Although the number of patients is not large enough
for powerful statistical analysis and patient characteristics
are quite heterogeneous, this study contributes to the
ongoing discussion on the diagnostic value of IGRA. IGRA
should not be employed as an alternative single screening
test as false negative results have been observed. Confir-
mation in larger studies, including cost-effectiveness in
different countries to determine the optimal screening
strategy, is warranted.
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